By Kelly Cloonan
Novo Nordisk said the Food and Drug Administration accepted its submission of a new drug application for a Wegovy pill to treat obesity amid a tense race to get an oral weight-loss medication on the market.
The Bagsvaerd, Denmark, company said Friday that if the application is approved, Wegovy would become the first oral formulation of a GLP-1 drug for chronic weight management.
The FDA's deadline to decide on the application will be in the fourth quarter, the company said.
The application is based on results from a phase 3 randomized, controlled trial evaluating the efficacy and safety of the drug over 64 weeks, the company said.
Last month, Eli Lilly said its oral obesity and type 2 diabetes treatment, called orforglipron, met its goals in the first of several studies expected this year. Companies such as Pfizer, Structure Therapeutics and Viking Therapeutics are also developing their own weight-loss pills.
Currently, all approved GLP-1s for weight loss are given by injection.
"We are entering a new era of obesity care where patients want individualized treatment plans that address their needs and provide choices, including oral formulations," said Anna Windle, senior vice president of clinical development, medical and regulatory affairs at Novo Nordisk.
Write to Kelly Cloonan at kelly.cloonan@wsj.com
(END) Dow Jones Newswires
May 02, 2025 15:33 ET (19:33 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。